Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Gains from Sales and Divestitures (2020 - 2025)

Outset Medical (OM) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $33000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 41.07% to $33000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $33000.0, a 41.07% decrease, with the full-year FY2025 number at $33000.0, down 41.07% from a year prior.
  • Gains from Sales and Divestitures was $33000.0 for Q4 2025 at Outset Medical, down from $56000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $708000.0 in Q4 2023 to a low of $19000.0 in Q4 2021.
  • A 5-year average of $208000.0 and a median of $56000.0 in 2024 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 1078.95% in 2022, then crashed 92.09% in 2024.
  • Outset Medical's Gains from Sales and Divestitures stood at $19000.0 in 2021, then soared by 1078.95% to $224000.0 in 2022, then surged by 216.07% to $708000.0 in 2023, then plummeted by 92.09% to $56000.0 in 2024, then plummeted by 41.07% to $33000.0 in 2025.
  • Per Business Quant, the three most recent readings for OM's Gains from Sales and Divestitures are $33000.0 (Q4 2025), $56000.0 (Q4 2024), and $708000.0 (Q4 2023).